Experimental gene therapy aims to trick immune system to attack brain tumors
NCT ID NCT06914479
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new combination treatment for children and young adults (ages 3-39) with recurrent malignant brain tumors that can be surgically removed. The treatment uses two genetically modified viruses injected into the tumor site, plus an oral anti-herpes drug, to kill cancer cells and stimulate the immune system to attack the tumor. The main goal is to check safety and find the best dose, with only 11 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified viruses (AdV-HSV1-TK and AdV-Flt3L) plus valacyclovir
What this could lead to
If it works, this could point toward a new treatment option for recurrent malignant brain tumors that are hard to treat.
What could go wrong
This is a very early phase 1 trial with only 11 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or improve survival, and there could be side effects from the viruses or valacyclovir.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MALIGNANT BRAIN NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact